Lilly-Boehringer Partnered Jardiance Slows Kidney Disease Progression, Data Shows

Boehringer Ingelheim and Eli Lilly And Co LLY said their diabetes drug Jardiance showed to slow the progression of chronic kidney disease.
The companies said the EMPA-KIDNEY phase 3 trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for chronic kidney disease.
In March, the trial was stopped early because an independent monitoring panel found the drug's benefit to be sufficiently clear.
When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo.
The results were announced today during the American Society of Nephrology (ASN)'s Kidney Week 2022.
EMPA-KIDNEY trial also demonstrated a significant reduction in all-cause hospitalizations (14%) vs. placebo, one of the pre-specified key secondary confirmatory endpoints.
The overall safety data was generally consistent with previous findings, confirming the well-established safety profile of Jardiance.
Reductions in other key secondary endpoints of hospitalization for heart failure, cardiovascular death, or all-cause death were not statistically significant. However, the power to detect this was limited by the number of events observed.
Price Action: LLY shares are down 0.79% at $358.82 on the last check Friday.